— Know what they know.
Not Investment Advice

ONESOURCE.NS NSE

Onesource Specialty Pharma Ltd.
1W: +2.4% 1M: +19.2% 3M: +57.2% YTD: +56.2% 1Y: +14.3%
₹1,837.90 ($19.21)
-23.90 (-1.28%)
 
Weekly Expected Move ±6.3%
₹1603 ₹1719 ₹1836 ₹1952 ₹2068
NSE · Healthcare · Biotechnology · Alpha Radar Buy · Power 62 · ₹210.3B mcap · 59M float · 0.899% daily turnover
Smart Money Score
Watch 0
Insider
Congress
ETF Holdings
Key Statistics
Market Cap₹210.3B ($2.2B)
52W Range1057-2248
Volume118,093
Avg Volume534,672
Beta1.61
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEONeeraj Sharma
Employees1,412
SectorHealthcare
IndustryBiotechnology
IPO Date2025-01-24
Star 1, Opp IIM Bangalore
Bengaluru 560076
IN
91 80 6784 0738
About Onesource Specialty Pharma Ltd.

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms